About the Company
AVEO Pharmaceuticals Inc. is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO's strategy is to focus its resources toward the development and commercialization of its product candidates in North America, while leveraging partnerships to support development and commercialization in other geographies. AVEO's lead candidate, FOTIVDA® (tivozanib), received U.S. Food and Drug Administration (FDA) approval on March 10, 2021 for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA® was approved in August 2017 in the European Union and other countries in the EUSA territory for the treatment of adult patients with advanced RCC. AVEO has previously reported promising early clinical data on ficlatuzumab (anti-HGF IgG1 mAb) in head and neck cancer, pancreatic cancer and acute myeloid leukemia and is conducting a randomized Phase 2 confirmatory clinical trial of ficlatuzumab for the potential treatment of head and neck cancer. AVEO's pipeline of product candidates also includes AV-380 (anti-GDF15 IgG1 mAb). AVEO has previously reported the acceptance of its investigational new drug application in the U.S. for AV-380 and its initiation of a Phase 1 clinical trial for the potential treatment of cancer cachexia. AVEO's earlier-stage pipeline includes monoclonal antibodies in oncology development, including AV-203 (anti-ErbB3 mAb) and AV-353 (anti-Notch 3 mAb). AVEO is committed to creating an environment of diversity and inclusion.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AVEO News
Aveo Pharmaceuticals
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include ...
AVEO Pharmaceuticals (AVEO) Stock Pops on European Licensing Agreement
TheStreet Ratings has this to say about the recommendation: We rate AVEO PHARMACEUTICALS INC as a Sell with a ratings score of D-. This is driven by multiple weaknesses, which we believe should ...
CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
In a release issued under the same headline on March 25 by AVEO Pharmaceuticals, the text in the second paragraph has been corrected to better reflect Dr. Braendle's clinical research experience.
David M Mott's Net Worth
Who is David M Mott? David M Mott has an estimated net worth of $2.21 Billion. This is based on reported shares across multiple companies, which include PhaseBio Pharmaceuticals Inc, Ra ...
Ravi Viswanathan's Net Worth
Ravi Viswanathan has an estimated net worth of $364 Million. This is based on reported shares across multiple companies, which include RHYTHM PHARMACEUTICALS, INC., Cascadian Therapeutics, Inc ...
VIDEO: How the Chevrolet Aveo Looks Like in Real-Life
Through a video, we'll tell you that the new version of the Chevrolet Aveo looks very little like the Aveo we all knew and ...
What does the Chevrolet Aveo Have to offer? The Details You Need to Know if You Live in the United States
The Chevrolet Aveo has been completely facelifted for 2024 and in this article, we compare two of the most noticeable aspects ...
CRVS Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers ...
Vertex Pharmaceuticals Inc VRTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
AVEO Pharmaceuticals, Inc.: AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer - - Formation of a Scientific Advisory Committee from world-renowned ...
AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”), an LG Chem company, today announced the appointment of Edgar E. Braendle, MD, PhD as AVEO Oncology’s new Chief Medical Officer.
AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer – – Formation of a Scientific Advisory Committee from world-renowned ...
Loading the latest forecasts...